December 2018, Volume 4, Issue 14

December 2018

Volume 4, Issue 14

This issue features a look at the consequences of medical errors, an update on the Cancer Moonshot Initiative, and more.

Table of Contents

December 2018 Issue

Biosimilars in Hematology: A Work in Progress

Saturday, December 1st, 2018
Recently, I was reviewing editorial content for ASH Clinical News, when I came across an article covering the U.S. Food and Drug Administration’s (FDA’s)...

#SHEmatology and #WOMANcology: Encouraging Women to Explore Careers and Leadership in Hematology and Oncology

Saturday, December 1st, 2018
Over the past 50 years, women in medicine have gained greater representation, with each generation of trainees moving closer to gender parity. The number...

My Fair MDs: Encouraging Doctors to Speak Plainly

Saturday, December 1st, 2018
“An Englishman's way of speaking absolutely classifies him. The moment he talks he makes some other Englishman despise him. One common language I'm afraid we'll never...

December 2018 Issue

ASH Presents Honorific Awards, Immunotherapy Researchers Receive Nobel Prize in Medicine, and more

Saturday, December 1st, 2018
American Society of Hematology Honors Distinguished Leaders at Annual Meeting At its 60th annual meeting, the American Society of Hematology (ASH) will present several distinguished...

ASH Announces New Executive Committee Members, Hosts MDS+AML MATTER Education Program, and more

Saturday, December 1st, 2018
And The Winners Are … ASH has announced the election of four new members to its Executive Committee for terms beginning after the 2018 ASH...

December 2018 Issue

Pulling Back the Curtain: Alexis Thompson, MD, MPH

Saturday, December 1st, 2018
In this edition, Alexis A. Thompson, MD, MPH, speaks about her career studying and working with patients with hemoglobin disorders – and discovering a...

When Mistakes Happen…

Saturday, December 1st, 2018
Medical error has been described as a public health emergency. Certainly, the numbers support this. Opioid abuse – today’s exemplar of public health emergency –...

Progress Report: Is the Moonshot Mission on Schedule?

Saturday, December 1st, 2018
A little less than three years ago, former President Barack Obama called on then Vice President Joseph Biden to lead the new National Cancer...

Hazardous to Your Health: Violence in the Health-Care Workplace

Saturday, December 1st, 2018
The headline-making events are familiar and chilling: a Boston cardiologist murdered in a hospital by the son of a deceased patient; an Indiana physician...

In Myeloma, Cure or Control?

Saturday, December 1st, 2018
Over the past two decades, the U.S. Food and Drug Administration (FDA) has approved a number of new treatments for patients with myeloma –...

Clearing the Pathway to a Cure: Interview with Adm. Brett P. Giroir, MD

Saturday, December 1st, 2018
When Adm. Brett P. Giroir, MD, was sworn in as Assistant Secretary for Health at the U.S. Department of Health and Human Services (HHS)...

The Middle Ages: Controversies in the Treatment of Adolescents and Young Adults With Leukemia

Saturday, December 1st, 2018
Over the past few decades, survival rates for pediatric patients with acute lymphocytic leukemia (ALL) have improved dramatically, with five-year survival rates now often...

December 2018 Issue

How I Treat in Brief: Using Molecular Genetic Tests to Evaluate Myelodysplastic Syndromes

Saturday, December 1st, 2018
David P. Steensma, MD, of Dana-Farber Cancer Institute and Harvard Medical School in Boston, discussed how to use results from molecular genetic tests in...

How I Treat in Brief: Managing Post-Thrombotic Syndrome

Saturday, December 1st, 2018
Anat Rabinovich, MD, of Soroka University Medical Center at the Ben-Gurion University of the Negev in Israel and Susan R. Kahn, MD, MSc, of...

How to Treat HELLP Syndrome

Saturday, December 1st, 2018
This month Saskia Middeldorp, MD, discusses treatment of HELLP (hemolysis, elevated liver enzymes, low platelet count) syndrome. And don't forget to check out next month's clinical...

How to Treat Ph-Negative Precursor B-Cell ALL and Ischemic Cardiomyopathy

Saturday, December 1st, 2018
This month, Anjali S. Advani, MD, discusses the management of Ph-negative ALL in a patient with ischemic cardiomyopathy. And don't forget to check out next...

Demystifying Multicolor Flow Cytometry

Saturday, December 1st, 2018
Flow cytometry has come a long way in the 80 years since its inception. The now highly sophisticated technique is an indispensable tool for...

December 2018 Issue

New Bill Bans Pharmacist Gag Orders

Saturday, December 1st, 2018
Congress has passed two bills prohibiting “gag clauses” in contracts between pharmacies and insurance companies or pharmacy benefit managers (PBMs). The legislation – one...

DOJ Approves the $69 Billion CVS-Aetna Merger

Saturday, December 1st, 2018
The U.S. Department of Justice (DOJ) approved the merger of the pharmacy and health-care provider CVS Health with insurer Aetna, paving the way for...

FDA Approves DNA-Based Blood Compatibility Test

Saturday, December 1st, 2018
The FDA granted approval to ID CORE XT, a molecular-based assay that can be used to determine blood donor and patient compatibility. ID CORE...

HHS Considering Requiring Pharmaceutical Ads to Include Prices

Saturday, December 1st, 2018
To provide incentives for pharmaceutical companies to lower drug prices, the U.S. Department of Health and Human Services (HHS) proposed requiring certain consumer-directed television...

Generics Manufacturers and Consumer Advocates Criticize Revamped NAFTA Deal

Saturday, December 1st, 2018
The recently updated North American Free Trade Agreement, now known as the U.S.-Mexico-Canada Agreement (USMCA), includes a 10-year exclusivity period for biologics, which is...

FDA Approves New Hemophilia A Drug

Saturday, December 1st, 2018
The FDA has approved emicizumab-kxwh as prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A...
WIB_icon

Preventing Hepatitis B Virus Reactivation During Immunochemotherapy for Lymphoma

Saturday, December 1st, 2018
Administering prophylactic antiviral treatment is effective in preventing hepatitis B virus (HBV) reactivation in patients with B-cell non-Hodgkin lymphoma (NHL) being treated with an...
WIB_icon

Do Children With CVC-Related Thromboses Need Anticoagulation Treatment?

Saturday, December 1st, 2018
Results from a prospective study of children who were hospitalized in a pediatric intensive care unit (PICU) revealed that the incidence of central vein...
WIB_icon

No Benefit With Adding Eltrombopag to Azacitidine in Patients With Higher-Risk MDS

Saturday, December 1st, 2018
In the phase III SUPPORT trial, researchers tested the hypothesis that concomitant administration of the thrombopoietin receptor agonist eltrombopag could ameliorate the thrombocytopenic effects...

FDA Approves Once-Weekly Carfilzomib Combo for Relapsed or Refractory MM

Saturday, December 1st, 2018
The FDA has approved a combination of once-weekly carfilzomib with dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma (MM). This...
WIB_icon

Early-Phase Trial Shows Venetoclax Plus HMA Has High Response Rates in Older Patients With...

Saturday, December 1st, 2018
In a phase Ib dose-escalation and dose-expansion study published in Blood, two-thirds of older patients with acute myeloid leukemia (AML) responded to the combination...

FDA Approves IV Treatment for HCL

Saturday, December 1st, 2018
The U.S. Food and Drug Administration (FDA) has approved moxetumomab pasudotox-tdfk for the treatment of adult patients with relapsed or refractory hairy cell leukemia...

Hospitals Launch Their Own Generic Drug Company

Saturday, December 1st, 2018
Responding to ongoing drug shortages and high drug prices, several major hospital groups in the U.S. have partnered to form Civica Rx, a new...

Medicare Part D Beneficiaries With Myeloma Receive Novel Therapies More Frequently, Have Better Survival...

Saturday, December 1st, 2018
People with myeloma who have prescription drug coverage under Medicare are less likely to use older cytotoxic chemotherapy and more likely to receive newly...
WIB_icon

Ruxolitinib Plus Azacitidine Improves Survival, Bone Marrow Fibrosis in Myelofibrosis

Saturday, December 1st, 2018
Adding azacitidine to ruxolitinib led to an “encouraging” spleen and bone marrow fibrosis response rate in patients with myelofibrosis (MF), compared with previous experience...

Sweeping Opioids Package Signed Into Law

Saturday, December 1st, 2018
On October 24, 2018, President Donald Trump signed legislation aimed at tackling the U.S. opioid epidemic. The package – representing legislation passed by the...

Duvelisib Approved for Patients with CLL or SLL

Saturday, December 1st, 2018
The FDA has approved the PI3K inhibitor duvelisib for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic...

FDA Approves NGS-Based Test for Patients With ALL or MM

Saturday, December 1st, 2018
The FDA authorized the next-generation sequencing (NGS)–based ClonoSEQ assay for the measurement of minimal residual disease (MRD) in patients with acute lymphocytic leukemia (ALL)...

Emicizumab Prophylaxis Reduces Bleeding Events in Hemophilia A Without Inhibitors

Saturday, December 1st, 2018
Treatment with emicizumab was associated with lower bleeding rates, compared with no prophylaxis, in patients with hemophilia A without inhibitors, according to findings from...

No Added Benefit When Hydroxyurea Is Combined With Aspirin in Middle-Aged Patients With Essential...

Saturday, December 1st, 2018
Cytoreductive treatment with hydroxyurea has been shown to reduce the risk of thrombosis in patients with essential thrombocythemia (ET) and high-risk features, which include...

NCI Releases 2020 Annual Plan and Budget Proposal

Saturday, December 1st, 2018
The National Cancer Institute (NCI) and its director Norman Sharpless, MD, recently released their annual plan and budget proposal for fiscal year 2020, in...

New Guidelines Call for “Seismic Shift” in Palliative-Care Delivery

Saturday, December 1st, 2018
In new guidelines published by the National Coalition for Hospice and Palliative Care, the National Consensus Project for Quality Palliative Care urges all health-care...

Researchers Identify Genetic Prognostic Predictors in Myeloproliferative Neoplasms

Saturday, December 1st, 2018
A team of European and American researchers have identified and characterized associations between specific genetic mutations and prognosis in patients with myeloproliferative neoplasms (MPNs),...

BCMA-Targeting CAR T-Cell Therapy Shows High Response Rate in Pretreated Myeloma

Saturday, December 1st, 2018
Multiple myeloma (MM) is a potential target for chimeric antigen receptor (CAR) T-cell therapies, according to final results from a first-in-human trial of B-cell...

A New Source of “Superwarfarin” Poisoning: Increased Bleeding Risk After Synthetic Cannabinoid Use

Saturday, December 1st, 2018
In the New England Journal of Medicine (NEJM), authors reported a case series of patients with synthetic cannabinoid–associated coagulopathy, identifying contamination with brodifacoum, or...

Eculizumab Reduces Hemolysis and Transfusion Dependency in Patients With Cold Agglutin Disease

Saturday, December 1st, 2018
Treatment with eculizumab, an inhibitor of the terminal complement pathway, reduced hemolysis and transfusion-dependence in patients with cold agglutin disease (CAD). However, it had...

Phlebotomy and Hydroxyurea Are Underused in Patients With Polycythemia Vera

Saturday, December 1st, 2018
Treatment with phlebotomy or hydroxyurea was associated with lower mortality among older patients with polycythemia vera (PV) who were considered at high thrombotic risk,...

December 2018 Issue

Every Patient Tells a Story: Using Narrative Medicine to Cure Disease

Saturday, December 1st, 2018
As part of the Education Program at the 2018 ASH annual meeting, three physician-writers will offer their take on the intersection of storytelling, writing,...

Myeloma Therapy: From Diagnosis to Relapse

Saturday, December 1st, 2018
This year’s Education Program takes a new approach to disease-specific content: In two Special Education Sessions, “Approach to the Treatment of the Young, Fit...

ASH-a-Palooza: Trainee Day. Reimagined.

Saturday, December 1st, 2018
The “Trainee Day” that attendees may know from past annual meetings has been reimagined as ASH-a-Palooza – a new educational experience that will offer...

Serving the Next Generation of Hematologists: Interview with Reed E. Drews, MD

Saturday, December 1st, 2018
Reed E. Drews, MD, recipient of the 2018 Mentor Award in education, explains how he found his home at Beth Israel Deaconess Hospital, Boston...

For the Love of the Lab: Interview with John E. Dick, PhD

Saturday, December 1st, 2018
John E. Dick, PhD, recipient of the 2018 Mentor Award in basic science, tells us about his career in the lab – from working...

Get Your Blood Pumping: High-Performance Hematology

Saturday, December 1st, 2018
In the “High-Performance Hematology: Elite Athletes and Weekend Warriors” session in this year’s Education Program, session chair Stephan Moll, MD, PhD, and speakers will...

SHARE